Open loot of Pharmaceutical Companies.

Pawan Kumar Bansal: Gustakhi Maaf Haryana

Open loot of Pharmaceutical Companies.How pharma companies are minting money/ cheating ailing patients by circumventing legal provisions of the statues is evident from this life- saving drug product ( a forth generation antibiotic) mostly given post surgery.

This formulation contains “Meropenem” which is active pharm ingredient required by the body as it is therapeutical active. While Disodium EDTA is inactive and not required by the body as well the formulation. It appears to have been added in the product to circumvent clutches of DPCO 2013- a central price control order/law under Essential Commodity Act 1956.

The manufacturer has labeled its MRP as Rs 5400/- while as per DPCO 2013, it should have been around 1000/-.
This is a ploy to get out of DPCO 2013.

This amounts to cheating to the ailing mankind. Why additional unnecessary drug/salt (Disodium EDTA) is injected in to the body of patient (at MRP of 5400/- ) which is not needed.

As per the label it appears to be a product manufactured at a WHO-GMP Certified Pharma Unit ??.

CDSCO and State drug Regulators to look in to and save the poor patients from clutches of such unscrupulous manufacturer / marketers.
Retired Drugs Controller Haryana G K ,Singal told “ Gustakhi Maaf Haryana “There is need to curb such malpractice by the Drug regulators entrusted with duties under Drugs Act.

Related Posts

  • Pharma
  • May 20, 2025
  • 63 views
Zydus Wellness posts 30% profit growth in FY25, Q4 net sales up 17% YoY

For the quarter ended March 31, 2025, Zydus Wellness reported 17% year-on-year growth in net sales at ₹9,106 million, up from ₹7,780 million in Q4 FY24. Adjusted net profit after…

  • Pharma
  • May 20, 2025
  • 62 views
Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin, which plans to develop the specialty business, is eyeing higher revenue share from its complex generics portfolios in the US and Europe. Moreover, with a pipeline of over 200…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Zydus Wellness posts 30% profit growth in FY25, Q4 net sales up 17% YoY

Zydus Wellness posts 30% profit growth in FY25, Q4 net sales up 17% YoY

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Lupin to boost complex generics in US, EU; eyes chronic growth in India

Growth Triggers Line Up for Divi’s Labs

Growth Triggers Line Up for Divi’s Labs

From generic drugs to vaccines, Indian pharma industry is transforming lives worldwide

From generic drugs to vaccines, Indian pharma industry is transforming lives worldwide